Plasma levels of D-dimer in lung carcinoma: Clinical and prognostic significance

Cancer

Volumn 97, Issue 12, 2003, Pages 3044-3052

  Buccheri, Gianfranco ^a   Torchio, Pierfederico ^b   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Blood coagulation; D dimer; Lung carcinoma; Prognosis

Indexed keywords

D DIMER; LACTATE DEHYDROGENASE; TISSUE POLYPEPTIDE ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; FIBRINOLYSIS; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION;

ADULT; AGED; CARCINOMA, BRONCHOGENIC; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0038052293     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11432     Document Type: Article

References (39)

1. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris, 3rd edition. Paris: J-B. Balliere et Fils, 1865:654-712.
2. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am. J. Clin. Pathol. 1987;88:596-602.
3. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18:353-372.
4. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am. 1996;10:457-484.
5. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trosseau's syndrome revisited. Blood. 1983;62:14-31.
6. Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost. 1990;16:230-235.
7. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999;25:167-172.
8. Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornestein DL. Clotting factors in tumor tissue: implications for cancer therapy. Blood Coagul Fibrinolysis. 1990;1:71-78.
9. Lebeau B, Chastang C, Brechot J-M, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994;74:38-45.
10. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989;7:993-1002.
11. Wojtukiewicz MZ, Zacharski LR, Moritz DM, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis. 1992;3:429-437.
12. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis. 1993;4:249-254.
13. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 1993;103:196-200.
14. Gabazza EC, Taguchi O, Yamakami T, et al. Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer. Eur J Cancer. 1994;30A: 1276-1281.
15. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997;52:563-565.
16. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications [see comments]. Eur J Cancer. 1997;33:50-55.
17. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001; 17:667-673.
18. Junker K. Prognostic factors in Stage I/II non-small cell lung cancer. Lung Cancer. 2001;33(Suppl 1):S17-S24.
19. World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag, 1991.
20. Mountain CF. Revisions in the International System for Staging Lung Cancer [see comments]. Chest. 1997;111:1710-1717.
21. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000;117:1247-1255.
22. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:199-205.
23. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer. 1986;57:2389-2396.
24. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer. 1987;60:42-50.
25. Buccheri G. Chemotherapy and survival in non-small cell lung cancer. The old vexata questio. Chest. 1991;99:1328-1329.
26. Siegel S. Nonparametric statistics for the behavioral sciences. New York: MacGraw Hill, 1956.
27. Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457-481.
28. SAS Institute Inc. SAS/STAT user guide [computer program]. Cary, NC: SAS Institute Inc., 2000.
29. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. Br J Cancer. 1977;35: 1-39.
30. Cox DR. Regression models and life tables. J R Statist Soc. 1972;34:187-220.
31. McCullagh RJ, Nelder JA, editors. Generalized linear models. Cambridge: Chapman and Hall University Press, 1988.
32. Francis CW, Marder VJ. Mechanism of fibrinolysis. In: Coller B, editor. Williams hematology (5th edition). New York: McGraw-Hill, 1995:1252-1260.
33. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389-395.
34. Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol. 1999;75:397-400.
35. Mirshahi SS, Pujade-Lauraine E, Soria C, et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer. 1992;69:2289-2292.
36. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388-394.
37. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998;28:373-378.
38. Rella C, Coviello M, De Frenza N, et al. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125. Tumori. 1993;79:347-351.
39. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001;12:51-58.